The product lifespan is extended by the use of asymmetric membranes! Additionally, it demonstrates maximum flow rate and throughput performance!
The "AcroPak Capsule Filter - Supor EKV Membrane" extends product life due to the Mach V asymmetric membrane, while demonstrating maximum flow rate and throughput performance. The "AcroPak 20 - Supor EKV," designed for small to medium volume filtration, is disposable, reducing operational and related costs. It is suitable for filtering fluids containing low concentrations of proteins, preservatives, and other important components, making it ideal for filtering aqueous solutions, cell culture media, and serum. 【AcroPak 20 - Supor EKV Features】 ■ Design suitable for small to medium volume filtration ■ Product is disposable ■ System is scalable ■ Testing during scale-up can be significantly reduced ■ Testing costs are greatly reduced *For more details, please refer to the PDF document or feel free to contact us.
Inquire About This Product
basic information
【Lineup】 ■AcroPak 20・Supor EKV ■AcroPak 200・Supor EKV ■AcroPak 400・800・1500・Supor EKV *For more details, please refer to the PDF document or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
【Application】 ＜AcroPak 20・Supor EKV＞ ■ Suitable for the filtration of aqueous solutions, cell culture media, and serum. ■ Adapted for the filtration of fluids containing low concentrations of proteins, preservatives, and other important components. ■ Filtration of media and buffers. ＜AcroPak 200・Supor EKV＞ ■ Designed for the rapid processing of difficult-to-filter solutions such as serum, media supplemented with serum, and ascitic fluid. ■ Suitable for rapid filtration or when quick processing is essential. ＜AcroPak 400・800・1500・Supor EKV＞ ■ Large-capacity filtration of a wide range of fluids such as buffers, biological solutions, and cell culture media. *For more details, please refer to the PDF document or feel free to contact us.
Company information
Cytiva and Pall Life Sciences have merged their businesses and will officially launch under the "Cytiva" brand on May 1, 2023. Under our mission of "Advancing therapies, faster," we will integrate both organizations and focus even more on supporting the development and manufacturing of better therapies for patients as a stronger global provider of technologies and services. The new Cytiva will offer a broader and deeper expertise and a rich lineup of products and services to better support various customers involved in research and the manufacturing and development of biopharmaceuticals, enabling them to deliver therapies to patients more quickly, from discovery to delivery. With a rich history spanning several hundred years, Pall Life Sciences and Cytiva, as part of the Danaher Group, will continue to unite to provide better services to our customers.